168 related articles for article (PubMed ID: 34806206)
1. Chemotherapy-associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies.
Veeder JA; Hothem LN; Cipriani AE; Jensen BC; Rodgers JE
Pharmacotherapy; 2021 Dec; 41(12):1066-1080. PubMed ID: 34806206
[TBL] [Abstract][Full Text] [Related]
2. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Chemotherapy Induced Cardiomyopathy.
Payne DL; Nohria A
Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity in anthracycline therapy: Prevention strategies.
Cruz M; Duarte-Rodrigues J; Campelo M
Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.
Sayed A; Abdelfattah OM; Munir M; Shazly O; Awad AK; Ghaith HS; Moustafa K; Gerew M; Guha A; Barac A; Fradley MG; Abela GS; Addison D
Eur J Cancer; 2022 Jul; 169():82-92. PubMed ID: 35524992
[TBL] [Abstract][Full Text] [Related]
8. Risk of Cardiomyopathy in Breast Cancer: How Can We Attenuate the Risk of Heart Failure from Anthracyclines and Anti-HER2 Therapies?
Kimmick G; Dent S; Klem I
Curr Treat Options Cardiovasc Med; 2019 May; 21(6):30. PubMed ID: 31152324
[TBL] [Abstract][Full Text] [Related]
9. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
11. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
12. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
[TBL] [Abstract][Full Text] [Related]
13. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
14. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
[TBL] [Abstract][Full Text] [Related]
15. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.
Abdel-Qadir H; Ong G; Fazelzad R; Amir E; Lee DS; Thavendiranathan P; Tomlinson G
Ann Oncol; 2017 Mar; 28(3):628-633. PubMed ID: 28028033
[TBL] [Abstract][Full Text] [Related]
16. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.
Liu C; Chen H; Guo S; Liu Q; Chen Z; Huang H; Zhao Q; Li L; Cen H; Jiang Z; Luo Q; Chen X; Zhao J; Chen W; Yang PC; Wang L
Biomed Pharmacother; 2023 Oct; 166():115373. PubMed ID: 37647693
[TBL] [Abstract][Full Text] [Related]
17. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
Varghese SS; Eekhoudt CR; Jassal DS
Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
[TBL] [Abstract][Full Text] [Related]
19. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
20. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
Bourke JP; Bueser T; Quinlivan R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
